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Long-Term Prognosis of Plantar Fasciitis
A 5- to 15-Year Follow-up Study of 174 Patients
With Ultrasound Examination
Liselotte Hansen,*† MD, Thøger Persson Krogh,† MD, PhD, Torkell Ellingsen,‡ MD, PhD,
Lars Bolvig,§ MD, and Ulrich Fredberg,† MD, PhD
Investigation performed at Regional Hospital Silkeborg, Silkeborg, Denmark,
and Stadium Clinic, Aarhus, Denmark
Background: Plantar fasciitis (PF) affects 7% to 10% of the population. The long-term prognosis is unknown.
Purpose: Our study had 4 aims: (1) to assess the long-term prognosis of PF, (2) to evaluate whether baseline characteristics (sex,
body mass index, age, smoking status, physical work, exercise-induced symptoms, bilateral heel pain, fascia thickness, and
presence of a heel spur) could predict long-term outcomes, (3) to assess the long-term ultrasound (US) development in the fascia,
and (4) to assess whether US-guided corticosteroid injections induce atrophy of the heel fat pad.
Study Design: Cohort study; Level of evidence, 3.
Methods: From 2001 to 2011 (baseline), 269 patients were diagnosed with PF based on symptoms and US. At follow-up (2016),
all patients were invited to an interview regarding their medical history and for clinical and US re-examinations. Kaplan-Meier
survival estimates were used to estimate the long-term prognosis, and a multiple Cox regression analysis was used for the
prediction model.
Results: In all, 174 patients (91 women, 83 men) participated in the study. All were interviewed, and 137 underwent a US
examination. The mean follow-up was 9.7 years from the onset of symptoms and 8.9 years from baseline. At follow-up, 54% of
patients were asymptomatic (mean duration of symptoms, 725 days), and 46% still had symptoms. The risk of having PF was
80.5% after 1 year, 50.0% after 5 years, 45.6% after 10 years, and 44.0% after 15 years from the onset of symptoms. The risk was
significantly greater for women (P < .01) and patients with bilateral pain (P < .01). Fascia thickness decreased significantly in both
the asymptomatic and symptomatic groups (P < .01) from 6.9 mm and 6.7 mm, respectively, to 4.3 mm in both groups. Fascia
thickness (P¼ .49) and presence of a heel spur (P¼ .88) at baseline had no impact on prognosis. At follow-up, fascia thickness and
echogenicity had normalized in only 24% of the asymptomatic group. The mean fat pad thickness was 9.0 mm in patients who had
received a US-guided corticosteroid injection and 9.4 mm in those who had not been given an injection (P ¼ .66).
Conclusion: The risk of having PF in this study was 45.6% at a mean 10 years after the onset of symptoms. The asymptomatic
patients had PF for a mean 725 days. The prognosis was significantly worse for women and patients with bilateral pain. Fascia
thickness decreased over time regardless of symptoms and had no impact on prognosis, and neither did the presence of a heel
spur. Only 24% of asymptomatic patients had a normal fascia on US at long-term follow-up. A US-guided corticosteroid
injection did not cause atrophy of the heel fat pad. Our observational study did not allow us to determine the efficacy of different
treatment strategies.
Keywords: long-term prognosis; prognosis; plantar fasciitis; heel spur; human; plantar heel pain; ultrasound; heel fat pad;
corticosteroid
The plantar fascia is a thickened, fibrous sheet of connec-
tive tissue that originates from the medial tubercle of the
calcaneus and fans out, attaching to the plantar plates of
the metatarsophalangeal joints and caput of the fifth meta-
tarsal bones. It provides support for the longitudinal arch
and serves as a dynamic shock absorber.17,28 Plantar fascii-
tis (PF) is one of the most frequent causes of heel pain.14,17
It occurs in 7% to 10% of the population over a lifetime and
has a significantly negative impact on foot-specific and gen-
eral health–related quality of life.6,15 PF is often a syn-
drome resulting from repeated trauma.28 The risk factors
are thought to be high body mass index (BMI) or sudden
weight gain, excessive running, prolonged standing/
walking occupations, work-related weightbearing activities,
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limited ankle dorsiflexion, cavus (high-arched) foot, and pes
planus (excessive foot pronation). The scientific evidence for
these theories is slight.2,12 The diagnosis is primarily based
on symptoms (heel pain duringwalking) and clinical findings
(pressure pain over the anteromedial aspect of the inferior
heel).2,6,12,33 Ultrasound (US) is often used to confirm the
diagnosis of PF and to rule out other causes of heel pain.29
US is a noninvasive, widely available, and inexpensive imag-
ing technique for assessing fascia abnormalities.1,13,16,25
Many treatments are available for PF,31 but the results
are not convincing. Recommendations include reduced
activity, stretching, insoles, slowly increased rehabilitation
(including strength training) within pain limits, avoidance
of barefoot walking, nonsteroidal anti-inflammatory drugs
(NSAIDs), shockwave therapy, and injections with a corti-
costeroid or platelet-rich plasma. Only rehabilitation
(eccentric training and slow heavy-strength training) and
corticosteroid injections (in the short term) have documen-
ted effects.26,31 Shockwave therapy and platelet-rich
plasma seem in some studies to be effective,21 although
documentation is modest.3 Earlier studies have shown that
up to 49% of the patients with PF are symptomatic 1.5 to 5
years after the onset of symptoms.4,5,22,27,35 Despite the
frequent occurrence of the condition both inside and outside
the sports environment, the long-term prognosis has only
been sparely investigated.
Our study had 4 aims: (1) to assess the long-term prog-
nosis of PF, (2) to evaluate whether baseline characteristics
(sex, BMI, age, smoking status, physical work, exercise-
induced symptoms, bilateral heel pain, fascia thickness,
and presence of a heel spur) could predict long-term out-
comes, (3) to assess the long-term US development in the
fascia, and (4) to assess whether US-guided corticosteroid
injections induce atrophy of the heel fat pad.
METHODS
Study Design and Participants
In the period from April 1, 2001, to December 28, 2011
(“baseline”), 269 patients were diagnosed and treated for
PF by the same 2 examiners (U.F. and L.B.) at Stadium
Clinic in Aarhus, Denmark. All patients were instructed
in rehabilitation according to the website www.sportnet-
doc.com and furthermore underwent a variety of treat-
ments as recommended by their physician. The 269
patients were contacted in 2016 (“follow-up”) and invited
to participate in this study, and 174 patients were included.
All patients gave informed consent before inclusion in the
study. They were interviewed and underwent a new clinical
evaluation and US examination of the plantar fascia of both
feet at Stadium Clinic or Regional Hospital Silkeborg. An
investigator (L.H.) conducted the follow-up examinations
and interviews.
Inclusion criteria consisted of documented PF based on
symptoms and clinical and US examination findings at
baseline. Exclusion criteria were (1) a chronic inflamma-
tory condition such as psoriasis, psoriatic arthritis, spondy-
loarthropathy, rheumatoid arthritis, or inflammatory
bowel disease, among others; and (2) age younger than 18
years at the onset of symptoms.
The Scientific Ethics Committee of Region Midtjylland,
Denmark, and the Danish Data Protection Agency
approved clearance for the study, which was performed in
accordance with the Declaration of Helsinki II and the
Oviedo Convention. This article was structured based on
the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) reporting guideline.34
Interview
As the first step of the evaluation, a telephone interview
was conducted regarding characteristics at the onset of
symptoms and at follow-up. The cause and presence of
unilateral or bilateral heel pain at the onset of symptoms
(as noted on the baseline report) were recorded. At follow-
up, the date of the disappearance of symptoms, relapse,
and applied treatments and medications were recorded.
At both baseline and follow up, information was collected
regarding weight, height, physical work (standing >50% of
the time), smoking status, and grading of pain on the plan-
tar fascia of both feet at rest, during walking and running,
and on pressure on a 0-to-10 numerical rating scale (NRS;
higher scores indicate worse outcomes). The patients were
classified into 2 groups at follow-up: an asymptomatic
group that scored 0 in all the categories of the NRS and
a symptomatic group that scored >0 on the NRS in either
rest, during walking, during running, or on pressure. If
the patient had bilateral heel pain at baseline, the most
painful foot at baseline was the one included in the study.
US Evaluation
The transducer was placed over the plantar aspect of the
hindfoot to examine the plantar fascia at its origin on the
calcaneus (Figure 1A) and then in the arch. Long-axis sono-
grams were obtained medial to the midline of the plantar
surface of the foot (Figure 1B), where the plantar fascia was
most well defined. A Toshiba US scanner with a 7.5-Hz
probe with a built-in water pillow was used for the US scans
in the period from 2001 to 2002, a Hitachi 8500 scanner
with a 12- to 14-Hz linear probe with Doppler was used in
*Address correspondence to Liselotte Hansen, MD, Guldsmedgade 25, 8000 Aarhus C, Denmark (email: liselotte.hansen91@gmail.com).
†Diagnostic Centre, Regional Hospital Silkeborg, Silkeborg, Denmark.
‡Department of Rheumatology, Odense University Hospital, Odense, Denmark.
§Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
One or more of the authors has declared the following potential conflict of interest or source of funding: This study was supported by the Danish
Rheumatism Association and the Research Fund of Hospital Unit Central Jutland.
Ethical approval for this study was obtained from the Scientific Ethics Committee of Region Midtjylland, Denmark, and the Danish Data Protection Agency
(50088, 1-16-02-575-15).
2 Hansen et al The Orthopaedic Journal of Sports Medicine
the period from 2003 to 2011, and aHitachi Preirus scanner
with an 18-Hz linear probe with Doppler and elastography
was used starting in 2011. Two examiners (U.F. [rheuma-
tologist] and L.B. [radiologist]), both with more than 20
years of US experience, performed the US at baseline.
Another investigator (L.H.) performed the follow-up exam-
inations, 80 (58.4%) of which were re-evaluated in blinded
fashion by one of the first examiners (U.F.). An interob-
server and intraobserver investigation similar to the study
by Rathleff et al25 was performed. The difference in fascia
thickness between the US scans (performed by L.H.) was
<0.2 mm.
The following were recorded from the US examination at
baseline and follow-up: (1) plantar fascia thickness, (2)
echogenicity, (3) bony erosions, (4) heel spurs, (5) ossifica-
tion, and (6) signs of (prior) fascia ruptures. The following
were recorded only at follow-up: (7) thickness of the heel fat
pad, (8) elastography (grading scale of 1-5), and (9) color
Doppler activity (grading scale of 0-4).19
The plantar fascia thickness was measured longitudi-
nally at the thickest point, either at the origin of the fascia
or in the arch of the foot (Figure 2). The heel fat pad was
measured vertically at the shortest distance from the
superficial border of the fascia to the skin above the calca-
neus (Figure 2). At least 3 measurements on 3 different still
pictures were used for each foot, and the average of the
measurements for fascia thickness and thickness of the
heel fat pad was registered. Echogenicity was subdivided
into 3 groups: group 1, normal fascia (isoechoic) with a
regular fibrillary appearance and fascia thickness <4 mm
(Figure 2A)25,30; group 2, doubtful pathological echogeni-
city (Figure 2B); and group 3, obviously diseased fascia that
was hypoechoic and thickened (>4 mm) and with a irregu-
lar or missing fibrillary appearance (Figure 2C).17,23
Elastography (Figure 3) of the plantar fascia was per-
formed by compressing the transducer with force applied
on the screen (green square in Figure 3) and was displayed
as a color-coded image in which the color represents the
relative stiffness in the fascia (red square in Figure 3).
Stiffness was categorized from 1 (stiffest) to 5: 1 is blue,
1.5 is >50% blue and <50% green, 2 is 50% blue and 50%
green, 2.5 is <50% blue and >50% green, 3 is green, 3.5 is
>50% green and <50% yellow/red, 4 is 50% green and 50%
yellow/red, 4.5 is<50% green and>50% yellow/red, and 5 is
yellow/red.18 Color Doppler activity was graded using a 0-
to-4 scale (grade 0: negative Doppler activity; grade 1: a
single vessel; grade 2: Doppler activity in <25% of the fas-
cia; grade 3: 25%-50% Doppler activity; and grade 4: Dopp-
ler activity in >50% of the fascia).19 Grading was estimated
in a 0.5-cm longitudinal part of the fascia with maximal
Doppler activity (region of interest), as described by Krogh
et al.19 Doppler settings were with a gain setting just below
the noise level and the V-scale set to 350.32
In the Cox regression analysis, we wanted to evaluate
whether baseline characteristics could predict the progno-
sis. An empirical cutoff value of 6.5 mm was used to see if
the thickness of the plantar fascia had a prognostic value
(ie, whether patients with a thickness>6.5 mmhad a worse
prognosis than those with a thickness between 4 mm [our
definition of a thickened fascia] and 6.5 mm).
Statistical Analysis
STATA software version 14 (StataCorp) was used for sta-
tistical analyses. A Kaplan-Meier survival analysis was
used to estimate the long-term prognosis of PF. A multiple
Cox regression analysis was used for the prediction model
on the baseline characteristics. A mixed-model analysis
was used to estimate the development of fascia thickness
in the affected feet from baseline to follow-up and for the
calculation of heel fat pad thickness and the distribution of
elastography between the affected and contralateral feet at
follow-up. A Z test was used for a comparison of mixed-
model analyses. Multinomial logistic regression was used
for the calculation of echogenicity. A P value of <.05 was
considered statistically significant.
RESULTS
Of the 269 patients, 258 were invited from April 1 to Sep-
tember 1, 2016, to participate in this study (Figure 4).
Eleven could not be located, 75 did not respond to our letter,
and 3 did not want to participate because of a busy schedule
or poor health. In all, 180 patients (69.7% ) agreed to par-
ticipate in this study, and 6 of them were excluded because
of age below 18 years at the onset of symptoms or other
chronic inflammatory conditions. In all, 174 (67.4%) were
enrolled in the study, and a telephone interview was car-
ried out in 172. Of the remaining participants, 1 answered
bymail, and 1 only had time for a short interview (including
information on medical history and the date on which
symptoms disappeared). Table 1 shows the participants’
characteristics. The patients varied in age from 20 to 79
years at the onset of symptoms and from 26 to 88 years at
follow-up, and BMI ranged from 17.8 to 43.3 kg/m2 at both
the onset of symptoms and follow-up. The mean follow-up
time was 9.7 years (range, 4.7-27.3 years) from the onset of
symptoms and 8.9 years from baseline. There were 91 (52%)
female and 83 (48%) male patients.
Figure 1. (A) The transducer was placed over the plantar
aspect of the hindfoot. (B) Long-axis sonogram of the plantar
fascia. C, calcaneus; FP, fat pad (blue line shows thickness);
PF, plantar fascia (red line shows thickness).
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On average, the patients had tried 3.8 different treat-
ments (range, 1-9). Overall, 93% of the patients tried
US-guided corticosteroid injections, 79% insoles, 66%
rehabilitation, 46% NSAIDs, 25% shockwave therapy,
21% acupuncture, 10% laser therapy, 9% US treatment,
2% surgery, and 34% tried other treatments such as mas-
sage, fish oil ingestion, and injections with platelet-rich
plasma (1%). In the asymptomatic group, 31.9% had at
least 1 relapse before they were permanently asymptom-
atic. During follow-up, 77.5% in the symptomatic group
stated they had experienced an asymptomatic period
(Table 1).
The follow-up results from the NRS showed that in the
symptomatic group, the patients scored, on average, 0.7
(95% CI, –0.7 to 2.0) during rest, 1.8 (95% CI, –0.2 to 4.0)
during walking, 2.8 (95%CI, 0.2 to 5.4) during running, and
2.1 (95% CI, –0.1 to 4.2) on pressure.
Long-Term Duration of Symptoms
At follow-up, therewere 94 (54%) patients in the asymptomatic
group and 80 (46%) in the symptomatic group. In the
asymptomatic group, the symptoms of PF had lasted a
mean of 725 days (range, 41-4018 days) before symptoms
disappeared. The Kaplan-Meier survival function
(Figure 5) indicated that the risk of having PF was 80.5%
(95% CI, 73.5-85.6) after 1 year, 50.0% (95% CI, 42.4-57.1)
after 5 years, 45.6% (95% CI, 37.9-53.0) after 10 years, and
44.0% (95% CI, 35.9-51.8) after 15 years.
Cox Regression Analysis for the Prediction of
Outcomes Based on Baseline Characteristics
The multiple Cox regression analysis (Table 2) revealed
that the hazard rate ratio (HRR; the chance of being asymp-
tomatic per year) for the characteristics at baseline was 1
for men and 0.49 (95% CI, 0.30-0.80; P < .01) for women (ie,
for every 100 men cured per year, only 49 women were
cured per year). The HRR for unilateral heel pain was 1,
Plantar fasciis (PF) diagnosed,2001-2011
(n = 269)
Paents contacted
(n = 258)
Full interview
(n = 180)
Symptomac
(n = 80)
Included in the study
(N = 174)
Asymptomac
(n = 94)
Addional US
of the PF
(n = 70)
Addional US
of the PF
(n = 67)
Not possible to
contact, emigrated, or
deceased
(n = 11)
No response
(n = 75)
Did not wish to
parcipate (n = 3)
Age < 18 (n = 1)
Chronic inﬂammatory
condion (n = 5)
No interest in new US
(symptomac: n = 10)
(asymptomac: n = 27)
Figure 4. Study flowchart. US, ultrasound.
Figure 2. (1) Plantar fascia and (2) heel fat pad measurements on ultrasound. (A) Normal fascia with a regular fibrillar appearance.
(B) Doubtful pathological echogenicity. (C) Diseased fascia.
Figure 3. Elastography of the plantar fascia.
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and it was 0.33 (95% CI, 0.15-0.72; P < .01) for bilateral
pain. The remaining baseline characteristics of BMI, age,
smoking status, physical work, time from onset of symp-
toms to baseline, fascia thickness, and presence of a heel
spur were not significant (all P values >.05).
Follow-up US Evaluation
At follow-up, a new US examination was performed in 137
patients. Only 108 contralateral feet were used for a com-
parison, while the remaining 29 were excluded from the
comparison because they were symptomatic.
The fascia thickness at baseline was, on average, 6.9 mm
(range, 3.8-11.0 mm) in the asymptomatic group and 6.7 mm
(range, 4.3-12.5 mm) in the symptomatic group (Figure 6).
At follow-up, the fascia thickness was reduced to 4.3 mm
(95% CI, 3.5-5.1 mm) in the asymptomatic group and
TABLE 1
Participant Characteristicsa
Asymptomatic Group Symptomatic Group All
Participants, n (%) 94 (54) 80 (46) 174 (100)
Age, y
At onset of symptoms 48.5 (21.8-79.4) 44.5 (20.7-67.8) 46.7 (20.7-79.4)
At follow-up 57.7 (34.9-88.8) 54.2 (26.2-76.8) 56.1 (26.2-88.8)
Follow-up time (onset of symptoms to follow-up), y 9.8 (4.9-18.2) 9.6 (4.7-27.3) 9.7 (4.7-27.3)
Female sex, n (%) 42 (44.7) 49 (61.3) 91 (52.3)
Body mass index, kg/m2
At onset of symptoms 24.8 (19.2-43.3) 25.0 (17.8-40.5) 24.9 (17.8-43.3)
At follow-up 25.4 (19.4-43.3) 25.5 (17.8-36.3) 25.5 (17.8-43.3)
Physical work, n (%)
At onset of symptoms 37 (39.4) 43 (53.8) 80 (46.0)
At follow-up 32 (34.0) 29 (36.3) 61 (35.1)
Smoker, n (%)
At onset of symptoms 23 (24.5) 16 (20.0) 39 (22.4)
At follow-up 0 (0.0) 2 (2.5) 2 (1.1)
Exercise-induced symptoms, n (%) 76 (80.9) 56 (70.0) 132 (75.9)
Time from onset of symptoms to baseline, d 256.5 (4-1932) 360.7 (5-5478) 304.4 (4-5478)
Duration of symptoms, d 724.5 (41-4018) 3623.8 (2212-5035) —
No. of treatments tried 3.4 (1-8) 4.3 (1-9) 3.8 (1-9)
Relapse, n (%) 30 (31.9) 62 (77.5) 92 (52.9)
aData are shown as mean (range) unless otherwise specified.
TABLE 2
Cox Regression Analysis for Prediction of Outcomes
Based on Baseline Characteristics
Hazard Rate Ratio (95% CI) P Value
Sex <.01
Male 1
Female 0.49 (0.30-0.80)
Body mass index .09
25 kg/m2 1
>25 kg/m2 0.65 (0.40-1.06)
Age .05
40 y 1
>40 y 1.93 (0.99-3.73)
Smoking status .64
Nonsmoker 1
Smoker 0.88 (0.51-1.52)
Physical work .24
No 1
Yes 0.75 (0.46-1.20)
Heel pain <.01
Unilateral 1
Bilateral 0.33 (0.15-0.72)
Time to ultrasound .44
0.5 y 1
>0.5 y 1.22 (0.74-2.00)
Fascia thickness .49
6.5 mm 1
>6.5 mm 1.20 (0.72-1.98)
Heel spur .88
No 1
Yes 0.96 (0.56-1.63)
Figure 5. Kaplan-Meier survival function. X-axis: Time in
years since the onset of symptoms (year 0). Y-axis: Patients
who are symptomatic (1.00 ¼ 100% is symptomatic).
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4.3mm (95%CI, 3.3-5.3mm) in the symptomatic group (both
groups, P < .01). There was no statistically significant dif-
ference between the 2 groups (P¼ .66). The survival analysis
(P ¼ .36) and multiple Cox regression analysis (P ¼ .88)
(Table 2) showed that fascia thickness (6.5 mm and >6.5
mm) had no impact on the prognosis. At baseline, 100% had
US evidence of fascia abnormalities (see Figure 2). At follow-
up (Figure 7), 23.9% (95%CI, 13.7-34.1) in the asymptomatic
group had a normal fascia, 29.9% (95% CI, 18.9-40.8) a
doubtful fascia, and 46.2% (95% CI, 34.3-58.2) a diseased
fascia. In the symptomatic group, 5.7% (95% CI, 0.3-11.1)
had a normal fascia, 45.7% (95% CI, 34.0-57.4) a doubtful
fascia, and 48.6% (95% CI, 36.9-60.3) a diseased fascia.
The odds ratio for finding a normal fascia by US was 4.4
times (95% CI, 1.4-15.4) higher in the asymptomatic group
compared with the symptomatic group (P ¼ .02). No sig-
nificant difference was found for doubtful and diseased
fascias.
At baseline, 55.5% of patients had a heel spur. A heel
spur at baseline did not result in a poorer prognosis (P ¼
.88) (Table 2). At follow-up in the asymptomatic group,
64.2% had a heel spur on the affected foot and 41.5% on
the contralateral foot. In the symptomatic group, 65.7%
had a heel spur on the affected foot and 34.1% on the
contralateral foot.
Elastography was measured in 126 affected feet and 98
contralateral feet. The mean stiffness was 1.6 (95% CI, 1.1-
2.1) for the affected foot and 1.5 (95% CI, 1.0-1.9) for the
contralateral foot. There was no difference between the
affected and contralateral feet (P ¼ .96). Neither did we
find any difference between symptomatic and asymptom-
atic patients.
No partial or complete fascia rupture or color Doppler
activity was observed in any of the patients.
US-Guided Corticosteroid Injection and the
Association With Atrophy of the Heel Fat Pad
The mean fat pad thickness was 9.0 mm (95% CI, 7.0-10.9
mm) in the heels of patients who had received a corticoste-
roid injection and 9.4 mm (95% CI, 7.2-11.6 mm) in those
who had not been given an injection (P ¼ .66).
DISCUSSION
The long-term prognosis of PF is unknown, and patients
are usually informed that the condition will resolve in 1
to 2 years. In this study, we investigated the long-term
prognosis of PF based on the duration of symptoms and
US evaluation of the fascia.
The first aim was to assess the long-term prognosis in
patients with PF. The results showed that the risk of still
having PF after 5 years was 50.0%, 45.6% after 10 years,
and 44.0% after 15 years from the onset of symptoms. How-
ever, the symptomatic patients at follow-up had minor
symptoms (pain level, 2.8 [range, 1-10] on the NRS). The
patients with PF in this study belong to a subgroup with the
most severe conditions, with a mean duration of symptoms
at baseline of 304 days (range, 4-5478 days). In addition,
93% of the patients were treated with a US-guided cortico-
steroid injection, which is not a first line of treatment, and
thus an indication that it was a “difficult-to-treat” cohort.
Therefore, the participants investigated in this study are
not representative for all patients with PF.
Of the 269 invited patients, 75 (28%) did not respond to
our letter and were not included in the study. The patients
who did not respond probably had few or no symptoms and
therefore had little motivation to participate in the project.
Even though many asymptomatic patients joined the study
(54%), the prognosis would most likely have been better if
the 75 patients who did not respond had joined. However,
our results were similar to those of other studies investi-
gating PF prognosis, with 18% to 49% of the patients being
symptomatic after a follow-up of 1.5 to 5 years.4,5,10,22,35
Further, a study to assess the duration of symptoms in
very light cases of PF is difficult to conduct, as this group
of patients might never visit a physician because PF dis-
appears quickly. We used the survival curve as our statis-
tical tool to measure what the long-term prognosis was. PF
is a condition with periods of improvement and relapse,
and the survival curve is probably only a snapshot of real-
ity because some patients will relapse again.
24%
30%
46%
Asymptomac
Normal Doubul Sick
6%
46%
48%
Symptomac
Figure 7. Echogenicity of the plantar fascia in asymptomatic
and symptomatic patients at follow-up.
Figure 6. Development of fascia thickness in the affected foot
from baseline (time 0) to follow-up in the asymptomatic and
symptomatic groups.
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Patients with PF often receive a variety of (and often
multiple) treatments. In our study, the patients tried, on
average, 3.8 different treatments. Unfortunately, our
observational study does not allow us to determine the
efficacy of the different treatment strategies.
The majority of the symptomatic patients in this study
had minor symptoms at follow-up (level 2-3 on the NRS).
However, 5 patients still suffered considerably from the
condition and scored >7 during walking on the NRS, and
almost all the symptomatic patients did not run anymore
because they were afraid of having PF again.
The second study aim was to predict the baseline char-
acteristics that had an impact on the prognosis. A signifi-
cantly higher risk for long-lasting symptoms was found for
women and patients with bilateral heel pain in both the
survival analysis and multiple Cox regression analysis (all
P values <.02). This study is the first to find a higher risk
for women. The reason is unknown but could be related to
hormonal, physical, shoe wear, or some other factor. Fur-
ther research is required to better answer the reasons for
the higher risk in female patients. Bilateral heel pain was
also a risk factor. People predisposed to PF should have the
condition bilaterally because both sides are stressed
equally. If there is pain in one heel, the other heel compen-
sates, which eventually could result in pain in both heels.
However, our study found only a small percentage of
patients with bilateral heel pain. Most patients with uni-
lateral pain do have US findings on their contralateral heel.
Perhaps patients with bilateral involvement only focus on
the more symptomatic side.
Bilateral pain could represent a manifestation of an
inflammatory disorder, for example, spondyloarthritis or
psoriasis, which is known to increase the risk of entheso-
pathy. Although none of the patients in this study had a
history of an inflammatory arthritic condition and only 2 of
36 with bilateral pain had bony erosions, no patients under-
went a physical or serological examination to rule out a
diagnosis of inflammatory disease. Therefore, the possibil-
ity exists that an element of systemic disease in the present
study group could have gone unrecognized. In the study by
Furey10 with 116 patients, 29% were still symptomatic
after 5.2 years of follow-up. In that study, 16% had systemic
involvement, and most of these patients had bilateral
pain.10 Yet, because the mean follow-up in our study was
9.7 years, we would expect that any systemic disease would
become manifested. However, the majority of the patients
had unilateral heel pain, which is the most common type.
There was no impact of BMI, age, smoking status,
exercise-induced symptoms, physical work, time from onset
of symptoms to baseline, fascia thickness, or presence of a
heel spur at baseline on the prognosis in our study (all P
values >.05). Wolgin et al35 conducted a follow-up study of
100 patients with PF and found that 18%were symptomatic
after a follow-up of 47 months (range, 24-132 months). In
that study, overweight, bilateral pain, and those who had
symptoms for a prolonged period (>6 months) before seek-
ing medical attention had a significantly higher risk for
persistent pain. None of the patients in that study had
been investigated with US or magnetic resonance imag-
ing. The cohort in our study was similar to the patients in
the study byWolgin et al35 with regard to age, sex, number
of patients with bilateral pain, and duration of symptoms
before medical attention was sought, but a higher propor-
tion in our study had PF because of sports activities (76%
vs 18% in the Wolgin et al study). In contrast to Wolgin
et al,35 we did not find any significant correlation with
BMI. The reason could be that the cohort in our study was
different because 76% were active in sports. The fact that
we used the BMI from baseline in the calculation might
also be a reason because patients’ weight most likely
changed over the years.
Our third aim was to assess the US findings in the fascia
at follow-up. Fascia thickness of 6.5 mm or >6.5 mm had
no impact on the prognosis (P ¼ .49), and most of the
patients still had a thickened and hypoechoic fascia at
follow-up despite not having symptoms. We also conducted
a Kaplan-Meier analysis of fascia thickness <7 and 7, <8
and 8, and <9 and 9 mm but were still unable to find a
correlation between fascia thickness and PF prognosis. At
follow-up, the fascia thickness was reduced significantly in
both groups, demonstrating that the fascia approached nor-
mal thickness over time whether or not the patients had
symptoms. The reason could be uncertainty in themeasure-
ments. Yet, because the same examiner (U.F.) measured
fascia thickness at both baseline and follow-up and the
interobserver (U.F. and L.H.) and intraobserver (L.H.) reli-
ability was 0.5% to 6.7%, it seems unlikely.
The decrease in thickness could also be linked to age
or the use of corticosteroid injections. Genc et al11 showed
that corticosteroid injections, which 93% of their patients
received, reduced fascia thickness; the same result was
found by Krogh et al20 in patients with tennis elbow and
Fredberg et al9 in those with Achilles and patellar tendino-
pathies. The corticosteroid reduces fascia thickness proba-
bly by making the edema disappear by reducing
inflammation. However, because the corticosteroid’s effect
is short, fascia thickness should return to the same patho-
logical thickness after this period if the triggering overload
continues.
The reduced fascia thickness could also be a natural
development in fascia healing. The “iceberg theory” first
described by Fredberg et al8 could be an explanation for the
lack of correlation between symptoms and US findings. The
iceberg theory claims that an asymptomatic fascia under-
goes a process involving progressive changes, which can be
seen by US. When a given threshold is reached, the fascia
will be symptomatic (the tip of the iceberg). During the
treatment of a symptomatic fascia, many will be asymptom-
atic, but the US changes in the fascia will persist for a long
time, which increases the risk of it becoming symptomatic
again. This explains why 44% of elite soccer players in Den-
mark had an abnormal Achilles fascia on US and 18% had
an abnormal patellar fascia without having symptoms at
the start of the season, while a significant number of the
players with an abnormal fascia developed symptoms dur-
ing the season.7 It is likely that the same applies to PF.
No difference in elastography was found between the
affected and contralateral feet (P ¼ .96). A reason for this
might be that we looked at chronic and not acute conditions.
In addition, no positive color Doppler activity was found,
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even though high-end US equipment was used and the
scanner was set to maximum sensitivity. In general, Dopp-
ler is difficult to use in patients with PF because of the
thickness and consistency of the skin and fat pad overlying
the fascia. McMillan et al24 also found no Doppler activity
in patients with PF.
In the general population, heel spurs are feared because
many think that they cause the symptoms. However, we
found that a heel spur had no influence on either the devel-
opment or prognosis of PF (P ¼ .88) and that many patients
had a heel spur without having symptoms. Karabay et al17
and Furey10 reached the same conclusions.
We did not find any correlation with PF symptoms at
follow-up and fascia thickness, elastography, color Doppler,
or heel spurs. Many of the asymptomatic patients also had
an abnormal fascia at follow-up. The use of US at follow-up
in patients with PF is of limited value, and clinical signs
(NRS) may be a better way to follow the progress. However,
it is reasonable to think that the patients with an abnormal
fascia have a greater risk of having a relapse and that US is
a good tool to diagnose PF when patients have symptoms
and to rule out differential diagnoses.
The fourth aim of our study was to evaluate whether US-
guided corticosteroid injections result in atrophy of the heel
fat pad. A general fear with the use of corticosteroid injec-
tions is that they might result in atrophy of the heel fat pad
or cause fascia ruptures. The heel fat pad was not reduced
when the diseased, injected foot was compared with the
contralateral, noninjected healthy foot (P ¼ .66), and none
of the patients experienced a rupture of the plantar fascia
at follow-up. Genc et al11 found similar results.
Limitations
As stated earlier, 28% of the invited patients did not
respond to our letter, possibly skewing our results, since
people are more motivated to participate in a study when
they have symptoms compared to when they are asymp-
tomatic. Recall bias might be a factor in this study because
the patients had to remember when their symptoms
started 5 to 27 years before. We did, however, seek confir-
mation of this information in the medical records at base-
line. Furthermore, the asymptomatic patients had to
recall when their symptoms disappeared. Information bias
could also have been a problem because we do not know
how many times the patients were treated with the differ-
ent treatments, for how long they underwent rehabilita-
tion, and many other aspects of their medical history. Also,
we did not assess outcomes based on treatments because
we had no specific guidelines for the variety of treatments.
A randomized controlled trial must be conducted to inves-
tigate this.
Three different US machines were used in the study.
There could potentially be a small measurement uncer-
tainty between the machines, but it is most unlikely that
this would affect the measurements of fascia thickness and
heel fat pad thickness. In addition, the examiner (L.H.) was
not blinded when performing the US scans with regard to
knowing the status of the patient’s symptoms. This could
potentially influence the interpretation of the US findings.
However, the other examiner (U.F.) was blinded when he
assessed the stored images. Finally, we did not include a
healthy control group for US comparison. In future trials,
this could help to distinguish between US findings that are
specific to pathological changes in PF and findings that
occur as a natural part of aging.
CONCLUSION
In patients with severe PF, the risk of still having PF was
50.0% after 5 years, 45.6% after 10 years, and 44.0% after
15 years from the onset of symptoms. Female patients and
patients with bilateral heel pain had a significantly higher
risk of having continuing symptoms. BMI, age, time from
the onset of symptoms to baseline, smoking status,
exercise-induced symptoms, and physical work had no sig-
nificant impact on the prognosis in this study. The patients
tried, on average, 3.8 different treatments, and a US-
guided corticosteroid injection was the most frequently
applied treatment (93%).
The US examination revealed that only 24% of the
asymptomatic patients had a plantar fascia with a normal
appearance. Themean fascia thickness decreased over time
regardless of symptoms, and fascia thickness and the pres-
ence of a heel spur at baseline had no impact on the prog-
nosis. Color Doppler activity and elastography had no role
in the US evaluation of chronic PF. A US-guided corticoste-
roid injection was not a risk factor for atrophy of the heel fat
pad or fascia ruptures.
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